Annovis Bio, Inc.
Business
Annovis Bio is a late-stage clinical-stage biopharmaceutical company developing buntanetap, a small-molecule oral drug designed to inhibit the synthesis of neurotoxic proteins implicated in Alzheimer's disease and Parkinson's disease. The company is advancing buntanetap through pivotal Phase 3 trials in early AD and open-label extension studies in PD, with preclinical and clinical candidates ANVS405 and ANVS301 for acute brain injury and advanced dementia. Annovis operates primarily in the United States and select European sites, relying on third-party contract manufacturers and clinical research organizations for development and manufacturing.
Summary from 10-K filed 2026-03-13
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 25 | 20 | 39 | 17 | 8 | |
| General and administrative | 4 | 7 | 6 | 9 | 6 | |
| Total operating expenses | 30 | 27 | 45 | 26 | 15 | |
| Operating loss | −30 | −27 | −45 | −26 | −15 | |
| Interest income | 699,061 | 331,849 | 667,898 | — | — | |
| Other financing costs | — | −2 | — | — | — | |
| Change in fair value of warrants | 142,000 | 4 | −12 | — | — | |
| Total other income, net | 841,061 | 2 | −11 | 182,712 | 50,089 | |
| Net loss | −29 | −25 | −56 | −25 | −15 | |
| Basic (dollars per share) | −1.4 | −2.02 | −6.23 | −3.1 | −1.9 | |
| Diluted (dollars per share) | −1.4 | −2.31 | −6.23 | −3.1 | −1.9 | |
| Basic | 21 | 12 | 9 | 8 | 8 | |
| Diluted | 21 | 12 | 9 | 8 | 8 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2022 2022-09-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 20 | 11 | 6 | 28 | 32 | |
| Prepaid expenses and other current assets | 2 | 3 | 4 | 8 | 5 | |
| Total assets | 21 | 14 | 10 | 36 | 37 | |
| Accounts payable | 3 | 2 | 1 | 4 | 2 | |
| Accrued expenses | 1 | 2 | 3 | 4 | 680,830 | |
| Total current liabilities | 4 | 4 | 4 | 8 | 3 | |
| Warrant liability | 595,000 | 737,000 | 14 | — | — | |
| Total liabilities | 4 | 5 | 18 | 8 | 3 | |
| Commitments and contingencies (Note 6) | — | — | — | — | — | |
| Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding | — | — | — | — | — | |
| Common stock - $0.0001 par value, 70,000,000 shares authorized, 27,199,139 and 14,141,521 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 2,719 | 1,414 | 1,052 | 816 | 816 | |
| Additional paid-in capital | 181 | 144 | 103 | 82 | 81 | |
| Accumulated deficit | −164 | −135 | −110 | −54 | −46 | |
| Total stockholders' equity | 17 | 9 | −8 | 28 | 35 | |
| Total liabilities and stockholders' equity | 21 | 14 | 10 | 36 | 37 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −29 | −25 | −56 | −25 | −14 | |
| Stock-based compensation expense | 2 | 4 | 5 | 9 | 5 | |
| Change in fair value of warrants | −142,000 | −4 | 12 | — | — | |
| Non-cash other financing costs | — | 2 | — | — | — | |
| Prepaid expenses and other current assets | 2 | 1 | 3 | −7 | −270,788 | |
| Accounts payable | 284,542 | 1 | −3 | 3 | 346,218 | |
| Accrued expenses | −530,154 | −1 | −751,012 | 3 | 581,916 | |
| Net cash used in operating activities | −26 | −22 | −40 | −17 | −9 | |
| Proceeds from issuance of common stock, warrants, and pre-funded warrants, net | 35 | 19 | — | — | — | |
| Proceeds from exercise of common stock options, net | 0 | 0 | 8,385 | 4,613 | 95,102 | |
| Proceeds from exercise of warrants | — | 8 | — | — | — | |
| Net cash provided by financing activities | 35 | 27 | 17 | 4,613 | 47 | |
| Net increase in cash and cash equivalents | 9 | 5 | −23 | −17 | 38 | |
| Reduction in value of warrants related to exercises | — | 9 | 606,201 | — | — | |
| Cash paid for financing costs | — | 50,000 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Annovis Bio, Inc.'s CIK number?
Annovis Bio, Inc.'s SEC CIK number is 0001477845 (1477845). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Annovis Bio, Inc.'s SEC filings?
All of Annovis Bio, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Annovis Bio, Inc. last report earnings?
Annovis Bio, Inc. (ANVS) most recently filed an earnings 8-K with the SEC on May 15, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-062451). This is Annovis Bio, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Annovis Bio, Inc.'s most recent earnings 8-K?
Annovis Bio, Inc.'s latest earnings 8-K (Item 2.02) was filed May 15, 2026 under accession 0001104659-26-062451. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Annovis Bio, Inc.'s latest earnings 8-K →
Look up any company's CIK number →